Catenion, a biopharma-focused R&D strategy consulting firm, has analyzed the performance of the top-30 biopharma companies in 2018 and outlined major concerns for the future of innovation in drug development. 

To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion takes an approach that focuses on value.

Catenion updates its annual list of the year's top pharma R&D performers. R&D productivity declined for the first time since 2014. Mid pharmas continue to dominate the top 10, but big pharmas are making inroads.

Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth. This year Regeneron shoots to the top and Gilead drops to third place.

To evaluate the R&D productivity of the world’s 30 largest public pharmaceutical companies, as judged by total pharmaceutical sales, Catenion's methodology takes an approach that focuses on value.

Catenion updates its annual list of the year's top pharma R&D performers, based on R&D productivity and growth.